Its once-weekly dosing improves patient adherence, while strong clinical outcomes and widespread physician adoption further support its market leadership The type 2 diabetes mellitus is expected to account for the largest share during the forecast period in application market In 2025, the type 2 diabetes mellitus segment is expected to dominate the market with the largest market share of 74.5% due to the widespread adoption of GLP-1 receptor agonists, such as Ozempic and Trulicity, for managing Type 2 diabetes
Asia Pacific will experience the highest CAGR of 14.7% in the next period, 2026-2035
These trials showed that Retatrutides activation of GLP-1, GIP, and glucagon receptors can improve metabolic balance, enhance fat oxidation, and support weight management outcomes in study populations
Related Reading FDA Peptide Reclassification 2026: What It Means for Patients Peptides Back in the News: What Actually Matters Wellness and Longevity at Amanecia Health
Unlock the fat-burning power of an optimized metabolism and enhance your endurance with Liquid L-CARNITINE 3000
DallOlio, F
